| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF-492-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | IC392F | |||
| Carrier Free | MAB392-SP | |||
| Carrier Free | MAB392-500 | |||
| Carrier Free | IC392V-100UG | |||
| Carrier Free | IC392U-100UG | |||
| Carrier Free | IC392T-100UG | |||
| Carrier Free | IC392S-100UG | |||
| Carrier Free | IC392R-100UG | |||
| Carrier Free | IC392N-100UG | |||
| Carrier Free | IC392G-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF392-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 392-MG-010/CF | |||
| Carrier Free | 392-MG-050/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 492-MM-010/CF | |||
| Carrier Free | 492-MM-050/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35191-1mg | |||
| Carrier-Free | NBP2-35191-100ug | |||
| Carrier-Free | NBP2-35191-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35008-1mg | |||
| Carrier-Free | NBP2-35008-100ug | |||
| Carrier-Free | NBP2-35008-500ug | |||
![N/A CXCL9/MIG [HRP]](http://images.novusbio.com/fullsize2/DATA_CXCL9_DCX900_ELISA_646.jpg "N/A CXCL9/MIG [HRP]")
![N/A CXCL9/MIG [HRP]](http://images.novusbio.com/fullsize2/DATA_CXCL9_DCX900_ELISA_647.jpg)
![N/A CXCL9/MIG [HRP]](http://images.novusbio.com/fullsize2/CXCL9_DCX900_ELISA_75.jpg)
![Serum ELISA results of three protein biomarkers in renal transplantation.We measured the protein concentration of ten genes by ELISA in independent serum samples of 19 AR patients and 20 patients with stable (STA) graft function after renal transplant. The protein concentrations of PECAM1 (A), CXCL9 (B), and CD44 (C) were higher in the AR serum samples, as shown in the notched boxplots. When the notches about two medians do not overlap, the medians are roughly significantly different at about a 95% confidence level [54] . The circles are outliers. P-values were calculated using the Mann-Whitney U test. One of the AR samples was inadvertently lost during the PECAM1 experiment and could not be recovered. (D) Areas under the Receiver Operating Characteristic (ROC) curves used to distinguish AR from STA were 0.811, 0.864, and 0.761 for PECAM1, CXCL9, and CD44, respectively. Image collected and cropped by CiteAb from the following open publication (//dx.plos.org/10.1371/journal.pcbi.1000940), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/dcx900_human-cxcl9-mig-quantikine-elisa-kit-44202415433113.jpg)
![N/A CXCL9/MIG [HRP]](http://images.novusbio.com/fullsize2/DATA_CXCL9_MCX900_ELISA_966.jpg "N/A CXCL9/MIG [HRP]")
![N/A CXCL9/MIG [HRP]](http://images.novusbio.com/fullsize2/CXCL9_MCX900_ELISA_261.jpg)
![N/A CXCL9/MIG [Biotin]](http://images.novusbio.com/fullsize2/DATA_CXCL9_DY392_ELISA_1990.jpg "N/A CXCL9/MIG [Biotin]")
![N/A CXCL9/MIG [Biotin]](http://images.novusbio.com/fullsize2/DATA_CXCL9_DY492_ELISA_2065.jpg "N/A CXCL9/MIG [Biotin]")
![Western Blot: CXCL9/MIG Antibody [NBP1-31155] - Untreated (-) and treated (+) MDA-MB-231 whole cell extracts (30 ug) were separated by 15% SDS-PAGE, and the membrane was blotted with MIG antibody diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced](http://images.novusbio.com/fullsize/CXCL9-MIG-Antibody-Western-Blot-NBP1-31155-img0009.jpg "<b>Biological Strategies Validation. </b>Western Blot: CXCL9/MIG Antibody [NBP1-31155] - Untreated (-) and treated (+) MDA-MB-231 whole cell extracts (30 ug) were separated by 15% SDS-PAGE, and the membrane was blotted with MIG antibody diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: CXCL9/MIG Antibody [NBP1-31155] - A431 cells. Green: MIG protein stained by MIG antibody diluted at 1:1000. Blue: Hoechst 33342 staining.](http://images.novusbio.com/fullsize/CXCL9-MIG-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-31155-img0007.jpg)
![Immunohistochemistry-Paraffin: CXCL9/MIG Antibody [NBP1-31155] - Human lung cancer. MIG stained by MIG antibody diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/CXCL9-MIG-Antibody-Immunohistochemistry-Paraffin-NBP1-31155-img0010.jpg)
![Immunohistochemistry-Paraffin: CXCL9/MIG Antibody [NBP1-31155] - Lung adenocarcinoma; antibody dilution 1:250. Antigen Retrieval: TrilogyTM (EDTA based) buffer, 15min.](http://images.novusbio.com/fullsize/CXCL9-MIG-Antibody-Immunohistochemistry-Paraffin-NBP1-31155-img0005.jpg)
![Western Blot: CXCL9/MIG Antibody [NBP1-31155] - Untreated (-) and treated (+) MBA-MD-231 whole cell extracts (30 ug) were separated by 15% SDS-PAGE, and the membrane was blotted with CXCL9/MIG antibody (NBP1-31155) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.](http://images.novusbio.com/fullsize/nbp1-31155_rabbit-polyclonal-cxcl9-mig-antibody-910202420104423.jpg)
![SDS-Page: Mouse CXCL9/MIG Protein [NBP2-35191]](http://images.novusbio.com/fullsize/Mouse-CXCL9-MIG-Protein-SDS-Page-NBP2-35191-img0001.jpg "SDS-Page: Mouse CXCL9/MIG Protein [NBP2-35191]")
![SDS-Page: Human CXCL9/MIG Protein [NBP2-35008]](http://images.novusbio.com/fullsize/Human-CXCL9-MIG-Protein-SDS-Page-NBP2-35008-img0001.jpg "SDS-Page: Human CXCL9/MIG Protein [NBP2-35008]")